Viatris (VTRS) EBT Growth (1y) (2020 - 2026)
Viatris (VTRS) EBT Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -324.14% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.93% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -8.74% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 70.52% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 1.69% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 124.00% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.07 Bn | 7.41 Bn | 397.90 Mn | -101.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70.52% |
| Mar 31, 2026 | 92.01% |
| Dec 31, 2025 | 34.85% |
| Sep 30, 2025 | -108.73% |
| Jun 30, 2025 | 44.59% |
| Mar 31, 2025 | -1,613.69% |
| Dec 31, 2024 | 38.42% |
| Sep 30, 2024 | -77.50% |
| Jun 30, 2024 | -217.66% |
| Mar 31, 2024 | -36.60% |
| Dec 31, 2023 | -158.21% |
| Sep 30, 2023 | -5.92% |
| Jun 30, 2023 | -14.46% |
| Mar 31, 2023 | -38.82% |
| Dec 31, 2022 | 820.40% |
| Sep 30, 2022 | 113.86% |
| Jun 30, 2022 | 277.68% |
| Mar 31, 2022 | 219.53% |
| Dec 31, 2021 | 79.88% |
| Sep 30, 2021 | 190.45% |